What is the appropriate dosing regimen of buspirone (Buspar) for an adult patient with schizophrenia?

Buspirone is NOT recommended for treating schizophrenia

Buspirone has no established role in the primary treatment of schizophrenia and should not be used as monotherapy. The evidence provided addresses buspirone dosing only in contexts unrelated to schizophrenia (Alzheimer's disease, delirium) or as an investigational adjunctive agent in research settings.

Critical Context from Available Evidence

FDA-Approved Indication

Buspirone is FDA-approved exclusively as an anxiolytic for generalized anxiety disorder 1. The drug label contains no indication for schizophrenia treatment.

Evidence from Alzheimer's Guidelines (Not Applicable to Schizophrenia)

The only guideline-level dosing information provided relates to Alzheimer's disease management, where buspirone is suggested for mild to moderate agitation at:

• Initial dose: 5 mg twice daily
• Maximum: 20 mg three times daily (60 mg/day)
• Onset: 2-4 weeks to become effective 2

This dosing cannot be extrapolated to schizophrenia, as the pathophysiology and treatment goals differ fundamentally.

Research Evidence Shows Mixed and Concerning Results

Potential Adjunctive Use (Investigational Only)

When studied as an adjunct to antipsychotics (not monotherapy):

• Positive findings: One study showed 60 mg/day buspirone added to risperidone improved negative symptoms over 8 weeks 3. Another study using 5-10 mg/day with clozapine showed cognitive improvements 4. A 24-week trial demonstrated neurocognitive benefits with buspirone augmentation 5.

• Negative/neutral findings: Multiple studies found no significant cognitive benefit when buspirone was added to atypical antipsychotics 6, 7. A 6-week trial showed no improvement in cognitive function or symptoms 7.

Critical Safety Concern: Worsening Psychosis

Buspirone can paradoxically worsen psychosis in schizophrenia patients 8. A case report documented exacerbation of paranoia, aggression, and odd behaviors when buspirone was administered to a patient with schizoaffective disorder. The mechanism involves buspirone's antagonism at presynaptic dopamine D2, D3, and D4 receptors, which can increase dopaminergic metabolites rather than produce antipsychotic effects 8.

Current Schizophrenia Treatment Guidelines

The most recent schizophrenia treatment guideline (2025) makes no mention of buspirone 9. Standard treatment involves:

• First-line: Antipsychotic monotherapy (atypical agents preferred)
• Second-line: Alternative antipsychotic after 4 weeks of inadequate response
• Third-line: Clozapine for treatment-resistant cases

Clinical Recommendation

If a patient with schizophrenia requires anxiolytic treatment:

1. Optimize antipsychotic therapy first - many antipsychotics have anxiolytic properties
2. Address comorbid anxiety disorder separately if present after psychotic symptoms are controlled
3. If buspirone is considered for comorbid anxiety (off-label):
   • Start at 5 mg twice daily
   • Maximum 60 mg/day (based on research studies, not FDA approval)
   • Monitor closely for worsening psychosis - discontinue immediately if paranoia, aggression, or psychotic symptoms increase
   • Only use as adjunct to established antipsychotic therapy, never as monotherapy
   • Allow 2-4 weeks for anxiolytic effect

Important Caveats

• Bioavailability is only 4% after first-pass metabolism 8, requiring relatively high doses
• No pharmacokinetic interaction with haloperidol was found 10, suggesting safety with typical antipsychotics from a drug interaction standpoint
• Intranasal abuse potential exists and dramatically increases bioavailability, potentially worsening psychosis 8
• Patients with hepatic or renal impairment require dose reduction or avoidance 1

The safest approach is to avoid buspirone in schizophrenia unless treating a clearly documented comorbid anxiety disorder that has not responded to optimization of antipsychotic therapy, and only under close psychiatric monitoring.